We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Syncona Limited | LSE:SYNC | London | Ordinary Share | GG00B8P59C08 | ORD NPV |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.60 | 0.59% | 103.00 | 246,460 | 16:35:13 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 102.60 | 103.00 | 103.40 | 102.40 | 103.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Trust,ex Ed,religious,charty | 30.75M | 3.79M | 0.0059 | 173.56 | 654.4M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:37:34 | O | 12,500 | 103.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 12/12/2024 | 07:00 | UK RNS | Syncona Limited Transaction in Own Shares |
| 11/12/2024 | 10:35 | UK RNS | Syncona Limited iOnctura presents clinical data update |
| 11/12/2024 | 07:00 | UK RNS | Syncona Limited Transaction in Own Shares |
| 10/12/2024 | 07:00 | UK RNS | Syncona Limited Transaction in Own Shares |
| 09/12/2024 | 07:00 | UK RNS | Syncona Limited Transaction in Own Shares |
| 06/12/2024 | 14:55 | ALNC |  Syncona hails positive trial data for new Beacon Therapeutics drug |
| 06/12/2024 | 12:05 | UK RNS | Syncona Limited Beacon announces clinical data update |
| 06/12/2024 | 07:00 | UK RNS | Syncona Limited Transaction in Own Shares |
| 05/12/2024 | 07:00 | UK RNS | Syncona Limited Transaction in Own Shares |
| 04/12/2024 | 07:00 | UK RNS | Syncona Limited Transaction in Own Shares |
Syncona (SYNC) Share Charts1 Year Syncona Chart |
|
1 Month Syncona Chart |
Intraday Syncona Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 11/12/2024 | 11:13 | Wellcome to Syncona | 711 |
| 02/5/2020 | 22:59 | Synchronica - Major management change heralds new strategy | 2 |
| 28/1/2017 | 02:52 | Welcome to Syncona | 2 |
| 20/12/2016 | 15:28 | Synchronica - Mobile Technology - 2012 | 4,755 |
| 08/3/2012 | 00:18 | Synchronica SYNC - Mobile Phone Technology - 2011 | 3,347 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-12-12 16:37:36 | 103.00 | 12,500 | 12,875.00 | O |
| 2024-12-12 16:35:13 | 103.00 | 53,000 | 54,590.00 | UT |
| 2024-12-12 16:30:01 | 102.60 | 511 | 524.29 | O |
| 2024-12-12 16:22:00 | 102.40 | 252 | 258.05 | AT |
| 2024-12-12 16:15:50 | 102.70 | 37,500 | 38,512.50 | O |
| Top Posts |
|---|
Posted at 12/12/2024 08:20 by Syncona Daily Update Syncona Limited is listed in the Trust,ex Ed,religious,charty sector of the London Stock Exchange with ticker SYNC. The last closing price for Syncona was 102.40p.Syncona currently has 639,065,994 shares in issue. The market capitalisation of Syncona is £654,403,578. Syncona has a price to earnings ratio (PE ratio) of 173.56. This morning SYNC shares opened at 103p |
Posted at 11/12/2024 11:11 by the shuffle man Good news keeps flowing (see recent announcements) . These will hopefully rerate soon. There must be a large seller around as the current buy back is doing nothing to the share price. |
Posted at 19/11/2024 12:05 by the shuffle man Just listened to the webinar which was upbeat. They see significant intrinsic value within the portfolio not represented in the current NAV. Next inflexion point will come from Beacon Therapeutics in Dec 24. Results from a trial have been brought forward from 2025 so hopefully these will be good. Current share price seems to represent good value with continued newsflow to come. |
Posted at 18/11/2024 13:26 by the shuffle man Did not think we would see this share price weakness. At this rate we are going to drop below £1. It doesn't make sense. |
Posted at 11/11/2024 13:22 by spectoacc Not sure they've sold any yet - they've said they're holding the APAX position until it re-rates for eg, wouldn't be surprised if same with SYNC. ie a longer-term seller, but not a firesale.Happy to sit in SYNC - if they did sell & tank it, I'd buy more. |
Posted at 23/10/2024 07:20 by the shuffle man More positive news. Deutsche have a price target of £2.05Chris Hollowood, Chief Executive Officer of Syncona Investment Management Limited and Chair of Spur Therapeutics, said: "The data presented at ESGCT further demonstrates FLT201's potential to transform the lives of patients with Gaucher disease. The maturing data that we are seeing from the GALILEO-1 trial underlines the durability profile of FLT201 and reinforces the long-lasting potential of this therapy beyond current standard of care for the thousands of patients with the disease. Furthermore, the data de-risks Spur's technology and supports the advancement of the company's pre-clinical pipeline into more prevalent disorders, including Parkinson's disease. The delivery of this data at ESGCT is a key value inflection point for Spur, and we continue to support the company as it prepares to initiate a Phase III trial in CY202 |
Posted at 17/10/2024 13:36 by ferrox5 I heard Holloway speak about a week ago. His enthusiasm was mainly directed at Beacon, though their subsequent announcement doesn't seem to have done much for the price. |
Posted at 17/10/2024 10:48 by the shuffle man Should be news on Autolus on 16 November.8 Penny Stocks with Biggest Upside Potential According to Analysts Autolus Therapeutics plc (NASDAQ:AUTL) Share Price: $3.89 Upside Potential: 182.05% Number of Hedge Fund Holders: 24 Autolus Therapeutics (NASDAQ:AUTL) is a clinical-stage biopharmaceuticals company based in the United Kingdom. It develops programmed T cell therapies for treating autoimmune diseases and cancer and focuses on chimeric antigen receptor (CAR) T cell therapy. The company engineers controlled, targeted, and highly active T cell therapy product candidates designed to recognize target cells, break their defense mechanisms down, and eliminate them. It is doing so using a portfolio of proprietary and modular T-cell programming technologies. Autolus Therapeutics (NASDAQ:AUTL) also has a pipeline of product candidates to treat solid tumors, hematological malignancies, and autoimmune diseases. The company has partnered with several healthcare players to increase capital. This initiative includes a partnership with BioNTech, which added $600 million to the company’s balance sheet in Q1 2024. In addition, the company has a deal with Blackstone Life Sciences to provide around $250 million in financing for its drug development and commercialization. Blackstone’s interest in the company is due to its potential to deliver lifesaving treatments to cancer patients. The company’s AUTO6NG program initiated patient treatment in Q2, with plans to share additional publications and clinical data regarding the programs in the second half of 2024. The launch of Obe-cel is also expected to take place in the US market soon, with a PDUFA date set for November 16. Autolus Therapeutics (NASDAQ:AUTL) has submitted a Market Authorization Application (MAA) to the UK’s MHRA for Obe-cel. Overall, AUTL ranks SEVENTH among the 8 penny stocks with the biggest upside potential according to analysts. |
Posted at 26/9/2024 11:36 by cousinit It's a difficult one. Who knows where the share price may have been now without them?The relatively unloved sector, NAV retreating where there has not been a materially positive move forward for some time now and the likely Witan overhang all cast a shadow. I guess you've got to take the view (if you're holding on!) that they will to get their mojo back at some point and that a reduced share count which was executed at prices below 130p made a worthwhile NAV accretion. Appreciate that the market doesn't believe the NAV, but CRS was buying stock back around 80p late last year with a then NAV just over 100p. NAV now north of 170p. |
Posted at 05/6/2024 08:53 by the shuffle man Trading at a huge discount to NAV even if you take into account the fall in Autolus shares since the last NAV valuation. All recent news from portfolio companies seems to be positive and the share price has bounced from these levels in the past so i have initiated a position. |
Posted at 17/5/2024 07:23 by spectoacc Autolus seems unable to keep its pants up for long. But SYNC still seems cheap to me, even if sometimes seems the only thing supporting it is the perma-buy back.Edit - bought back in today. My buys having zero effect on the price, so a good chance I'll be averaging lower, but cheap is cheap. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
